Health and Fitness Health and Fitness
Mon, February 27, 2012
Sat, February 25, 2012
Fri, February 24, 2012
[ Fri, Feb 24th 2012 ] - Market Wire
BrainStorm Featured on CNBC
Thu, February 23, 2012
[ Thu, Feb 23rd 2012 ] - Market Wire
00 am ET
Wed, February 22, 2012
Tue, February 21, 2012
Mon, February 20, 2012
Sat, February 18, 2012
Fri, February 17, 2012
Thu, February 16, 2012
Wed, February 15, 2012
[ Wed, Feb 15th 2012 ] - Market Wire
Biogen Idec adquiere Stromedix
Tue, February 14, 2012

Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies


Published on 2012-02-21 06:16:22 - Market Wire
  Print publication without navigation


Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic... -- PALO ALTO, Calif., Feb. 21, 2012 /PRNewswire/ --

Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies

[ ]

PALO ALTO, Calif., Feb. 21, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: [ TELK ]) today announced that the Phase 2 investigator-led Telcyta trial in hematologic malignancies has been expanded to an additional investigational site, Memorial Sloan-Kettering Cancer Center (MSKCC).  Based upon the results observed in Stage 1 of the trial, which is being conducted at the Robert Wood Johnson University Hospital under the direction of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an additional 10 patients with chemotherapy resistant multiple myeloma may be enrolled.  Additional trial investigators at MSKCC are Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.    

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.

Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.

SOURCE Telik, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.telik.com ]


Publication Contributing Sources